CCO_Clin_Phase III J-ALEX Alectinib vs Crizotinib in ALK Inhibitor–Na.ppt

CCO Independent Conference Coverage*of the 2016 ASCO Annual Meeting, June 3 -7, 2016 Phase III J-ALEX: Alectinib vs Crizotinib in ALK Inhibitor–Naive, ALK-Positive NSCLC *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. This activity is supported by educational grants from Amgen, Ariad,Bayer Healthcare Pharmaceuticals, Celgene Corporation, Genentech, Incyte, Merck, and Taiho Pharmaceuticals. Alectinib in ALK Inhibitor–Naive ALK+ NSCLC (J-ALEX): Backgroun